Roche 454 Sequencing Systems Successfully Resolve Genetic Mutations in Blood Cancer Cases
Published: Thursday, December 13, 2012 Last Updated: Thursday, December 13, 2012
International study presented at ASH Meeting demonstrates the potential of 454 Sequencing Systems to comprehensively characterize an individual’s blood cancer type to guide personalized therapy decisions.
Full access to this article is for registered users only. Registration is free-of-charge and allows access to all content on our web communities.
Already registered? Then please log in at the top of the page.